# Core Task
Extract detailed pharmacological information about Antibody-Drug Conjugates (ADCs) from the literature, specifically identifying Key fields including ADC Name, Conjugate Type, Drug-Antibody Ratio (DAR), mAb, Linker, Payload, and Drug Status.
Literature to analyze: `dataset/ADCdb/ref2.pdf`, `dataset/ADCdb/ref4.pdf`, `dataset/ADCdb/ref5.pdf`

# Output Requirements & File Path
- Output format: A CSV file with the following columns (exactly matching the ground truth CSV headers). Use "N/A" for missing values.
  - `Paper`: The reference ID or filename of the paper (e.g., ref1).
  - `ADC Name`: The name of the Antibody-Drug Conjugate.
  - `mAb`: The specific monoclonal antibody used.
  - `Linker`: The type of linker used to connect the antibody and payload.
  - `Payload`: The cytotoxic payload delivered by the ADC.
  - `Conjugate Type`: The method or type of conjugation.
  - `DAR`: The Drug-Antibody Ratio.
  - `Drug Status`: The current clinical or development status of the ADC.
- Save Path: Save the result to: `/root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/adcdb_extract_1.csv`
- Intermediate Storage Path: All intermediate code generated during execution, downloaded files, and temporary results must be stored in `/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/adcdb_extract/`

# Output Example (For Reference Only)
Paper,ADC Name,mAb,Linker,Payload,Conjugate Type,DAR,Drug Status
ref2,Pseudo-ADC-X,Anti-Target-Y IgG1,Enzymatic linker,Cytotoxin Z,Site-specific,3.8,Phase 3
ref4,NextGen-ADC,Bispecific mAb,pH-sensitive linker,Potent Payload A,Cysteine conjugation,N/A,Preclinical

I'll start by creating a plan to extract ADC pharmacological information from the literature.

**Plan:**
1. [ ] Check if the PDF files exist and verify their paths
2. [ ] Read/extract text from ref2.pdf, ref4.pdf, and ref5.pdf
3. [ ] Analyze the content to extract ADC information (Name, mAb, Linker, Payload, Conjugate Type, DAR, Drug Status)
4. [ ] Create a structured dataset with the extracted information
5. [ ] Save the results to the specified CSV file path

Let me start by checking the files and reading them:

<execute>
import os
import pdfplumber
import pandas as pd

# Define paths
pdf_paths = [
    "dataset/ADCdb/ref2.pdf",
    "dataset/ADCdb/ref4.pdf",
    "dataset/ADCdb/ref5.pdf"
]

# Check if files exist
for path in pdf_paths:
    if os.path.exists(path):
        print(f"Found: {path}")
    else:
        print(f"NOT found: {path}")
</execute>
<observation>NOT found: dataset/ADCdb/ref2.pdf
NOT found: dataset/ADCdb/ref4.pdf
NOT found: dataset/ADCdb/ref5.pdf
</observation>
Let me check the database lake structure to find the correct paths:

<execute>
import os

# Check database lake
base_path = "./operation_env/database_lake"
print("Checking database lake...")
for root, dirs, files in os.walk(base_path):
    for file in files:
        if "ref" in file.lower() and ".pdf" in file.lower():
            print(os.path.join(root, file))
</execute>
<observation>Checking database lake...
</observation>
<execute>
import os

# Check current directory and look for dataset folder
print("Current directory:", os.getcwd())
print("\nLooking for dataset folder...")
if os.path.exists("dataset"):
    for root, dirs, files in os.walk("dataset"):
        for file in files:
            if ".pdf" in file:
                print(os.path.join(root, file))
else:
    print("dataset folder not found")

# Also check root
print("\nChecking /root...")
if os.path.exists("/root"):
    for item in os.listdir("/root"):
        print(f"  {item}")
</execute>
<observation>Current directory: /root/biodatalab

Looking for dataset folder...
dataset folder not found

Checking /root...
  .bashrc
  .profile
  autodl-fs
  autodl-pub
  .cache
  .codex
  .conda
  .config
  .dotnet
  .ipython
  .java
  .jupyter
  .local
  .mamba
  .mem0
  .ncbi
  .nv
  .nvm
  .parallel
  .ssh
  .tooluniverse
  .vscode-R
  .vscode-server
  autodl-tmp
  biodatalab
  miniconda3
  nltk_data
  tf-logs
  .bash_history
  .condarc
  .prodyrc
  .python_history
  .viminfo
  .wget-hsts
  .zshrc
  ncbi_error_report.txt
</observation>
<execute>
import os

# Check autodl-tmp folder
tmp_path = "/root/autodl-tmp"
if os.path.exists(tmp_path):
    print("autodl-tmp exists")
    for item in os.listdir(tmp_path):
        print(f"  {item}")
        
# Also check biodatalab
print("\nChecking biodatalab...")
bio_path = "/root/biodatalab"
if os.path.exists(bio_path):
    for item in os.listdir(bio_path):
        print(f"  {item}")
        if os.path.isdir(os.path.join(bio_path, item)):
            for subitem in os.listdir(os.path.join(bio_path, item)):
                print(f"    {subitem}")
</execute>
<observation>autodl-tmp exists
  .autodl
  biomni_v20260207_bash_log
  biomni_v20260207_evaluate_results
  biomni_v20260207_log
  biomni_v20260207_pred_results
  biomni_v20260207_tmp
  biomni_v20260208_bash_log
  biomni_v20260208_evaluate_results
  biomni_v20260208_log
  biomni_v20260208_pred_results
  biomni_v20260208_tmp
  mBodyMap
  resource
  hg19ToHg38.over.chain.gz
  biomni_v20250208_pred_results

Checking biodatalab...
  assistant
    __pycache__
    agent
    biorxiv_scripts
    commons
    model
    prompts
    task
    tool_biodatalab
    tool_biomni
    __init__.py
    env_desc_biodatalab.py
    env_desc_biomni.py
    interface.py
    llm.py
    utils.py
    version.py
  benchmark
    dataset
    gold_programs
    gold_results
    tasks
    verifiers
    README.md
    biodatalab.csv
    biodatalab_new.csv
    update_verified_tasks.py
    verified_task.json
  data
    pbmc3k_processed.h5ad
  evaluate_bash_scripts
    run_evaluate_batch_biomni_claude-haiku-4-5.sh
    run_evaluate_batch_biomni_claude-opus-4-5.sh
    run_evaluate_batch_biomni_doubao_seed_1_8.sh
    run_evaluate_batch_biomni_dpsk_v3_2.sh
    run_evaluate_batch_biomni_gemini-3-flash-preview.sh
    run_evaluate_batch_biomni_gemini-3-pro-preview.sh
    run_evaluate_batch_biomni_glm_4_7.sh
    run_evaluate_batch_biomni_gpt_5_1.sh
    run_evaluate_batch_biomni_gpt_5_2.sh
    run_evaluate_batch_biomni_kimi_2_5.sh
    run_evaluate_batch_biomni_qwen3_max.sh
  evaluate_results
    claude-haiku-4-5
    claude-opus-4-5
    deepseek-v3.2-fast
    doubao-seed-1-8
    gemini-3-flash-preview
    gemini-3-pro-preview
    glm-4.7
    gpt-5.1
    grok-4-1-fast-reasoning
    kimi-k2.5
    qwen3-max-2026-01-23
  log
    claude-haiku-4-5
    claude-opus-4-5
    deepseek-v3.2-fast
    doubao-seed-1-8
    gemini-3-flash-preview
    gemini-3-pro-preview
    glm-4.7
    gpt-5.1
    grok-4-1-fast-reasoning
    kimi-k2.5
    qwen3-max-2026-01-23
  mapper_logs
    mapper.log_734457_1770451996
  operation_env
    BatMeth2-master
    MethHaplo-main
    SAAMBE-3D-master
  paper_analysis
    analysis_100_tasks.py
  pred_results
    type
    GSE116315_family.soft.gz
    adcdb_extract_1.csv
    adcdb_extract_2.json
    antibody_seq_retrieval.fasta
    asmdb_retrieval.json
    atlas_retrieval_1.json
    bioka_retrieval.json
    cds_db_retrieval.json
    circmine_extract.csv
    circmine_retrieval.json
    cov_pdb_retrieval.json
    covpdb_integration_complex.csv
    covpdb_integration_protein.csv
    crost_retrieval.json
    ctr_db_retrieval.json
    cyanoimicsdb_extract.tsv
    cyanoomicsdb_extract.csv
    dda_extract.csv
    ddinter_retrieval.json
    disco_extract.csv
    dntppooldb_extract.csv
    fusionneoantigen_extract.json
    macc_extract.csv
    npcdr_extract_1.json
    npcdr_extract_2.csv
    npcdr_retrieval.json
    paper.txt
    pcmdb_extract.csv
    pharmgwas_extract.csv
    pronab_extract.csv
    ravar_extract.json
    rmsf_ca.json
    scan_retrieval.json
    scqtlbase_retrieval.json
    stemdriver_retrieval.json
    stemdriver_retrieval_temp.json
    tf_marker_retrieval.json
    themarker_extract_1.json
    themarker_extract_2.csv
  pred_results_new
    claude-haiku-4-5
    claude-opus-4-5
    deepseek-v3.2-fast
    doubao-seed-1-8
    gemini-3-flash-preview
    gemini-3-pro-preview
    glm-4.7
    gpt-5.1
    grok-4-1-fast-reasoning
    kimi-k2.5
    qwen3-max-2026-01-23
  tmp
    adcdb_extract
    asmdb_retrieval
    atlas
    bioka_retrieval
    cds_db_retrieval
    circmine_extract
    circmine_retrieval
    covpdb
    crost_retrieval
    ctr_db_retrieval
    dda_extract
    ddinter_retrieval
    disco_extract
    dntppooldb_extract
    fusionneoantigen_extract
    macc_extract
    npcdr_extract_1
    npcdr_extract_2
    npcdr_retrieval
    pcmdb_extract
    pharmgwas_extract
    pronab_extract
    ravar_extract
    scan_retrieval
    scqtlbase_retrieval
    stemdriver_retrieval
    test_pdb
    tf_marker_retrieval
    themarker_extract_1
    themarker_extract_2
    analyze_covalent.py
    analyze_covalent_v2.py
    download_pdbs.py
    download_pdbs_batch.py
    ecod.domains.txt
    entries.idx
    fetch_all_pdbs.py
    get_pdb_list.py
    parse_idx.py
    pdb_candidates.json
    pdb_ids.json
    query.json
    query_pdb.py
    query_test.py
  tmp_new
    claude-haiku-4-5
    claude-opus-4-5
    deepseek-v3.2-fast
    doubao-seed-1-8
    gemini-3-flash-preview
    gemini-3-flash-previewpcmdb
    gemini-3-pro-preview
    gemini-3-pro-previewpcmdb
    glm-4.7
    gpt-5.1
    grok-4-1-fast-reasoning
    kimi-k2.5
    qwen3-max-2026-01-23
  traitdata
    R
    data-raw
    data
    man
    vignettes
    .Rbuildignore
    .gitignore
    DESCRIPTION
    LICENSE.md
    NAMESPACE
    README.Rmd
    README.md
    traitdata.Rproj
  .env.template
  README.md
  elton_birds_species_list.csv
  env_install.sh
  environment.yaml
  environment.yml
  example_log_trajectory.json
  example_log_trajectory_zjt.json
  output.pdbqt
  process_pdbs.py
  retrieve_cyano.py
  run_evaluate_batch_biomni.py
  run_evaluate_batch_biomni.sh
  get_gwas.py
  run_evaluate_batch_biomni_for_bash.py
  run_evaluate_case_biomni.py
  run_evaluate_case_stella.py
  run_evaluate_case_tooluniverse.py
  run_only_evaluate.py
  run_qc_filtering.py
  1crn.pdb.gz
  run_qc_filtering_corrected.py
  count_genes.py
  5yuv.pdb.gz
  run_qc_filtering_corrected_v2.py
  6a1f.pdb.gz
  6a1g.pdb.gz
  run_qc_filtering_corrected_v3.py
  run_qc_filtering_final.py
  script.py
  metadata_script.py
  sasa_script.py
  sasa_script_v2.py
  process_drugs.py
  search_geo.py
  search_sra.py
  search_geo_v2.py
  final_extraction.py
  SRR31029759.sorted.bam
  fix_sra_extraction.py
  raw_counts_htseq.txt
  debug_extraction.py
  robust_search.py
  simple_search.py
  exhaustive_search.py
  fix_sra_linking.py
  GSE210066_metadata.csv
  manual_check_gse.py
  GSE210066_metadata_fixed.csv
  fix_sra_search.py
  final_sra_search.py
  tmp.json
  temp.json
  fix_final_v2.py
  retrieve_srrs.py
  GSE210066_cell_stats.csv
  ultimate_search.py
  search_af_2025.py
</observation>
<execute>
import os

# Check benchmark/dataset
benchmark_dataset = "/root/biodatalab/benchmark/dataset"
print("Checking benchmark/dataset...")
for item in os.listdir(benchmark_dataset):
    print(f"  {item}")
    if "adc" in item.lower():
        adc_path = os.path.join(benchmark_dataset, item)
        print(f"\nFound ADC folder: {adc_path}")
        for root, dirs, files in os.walk(adc_path):
            for file in files:
                print(f"    {os.path.join(root, file)}")
</execute>
<observation>Checking benchmark/dataset...
  ADCdb

Found ADC folder: /root/biodatalab/benchmark/dataset/ADCdb
    /root/biodatalab/benchmark/dataset/ADCdb/ref2.pdf
    /root/biodatalab/benchmark/dataset/ADCdb/ref4.pdf
    /root/biodatalab/benchmark/dataset/ADCdb/ref5.pdf
  ASMdb
  ATLAS
  BioKA
  COLOCdb
  COVID-19
  CancerMIRNome
  CancerProteome
  CancerSCEM
  CellCommuNet
  CellSTAR
  ClinicalOmicsDB
  CompoDynamics
  CovPDB
  CyanoOmicsDB
  DDA
  DDInter
  DIANA-miTED
  DISCO
  DRMef
  FusionNeoAntigen
  GPEdit
  Kincore
  M2OR
  MVIP
  MetazExp
  NPCDR
  OncoDB
  PCMDB
  PGS-Depot
  PLAbDab
  PlantPAD
  PncsHub
  ProNAB
  RAVAR
  SCoV2-MD
  SCovid
  TF-Marker
  TheMarker
  VarEPS
  ViMIC
  dNTPpoolDB
  iNClusive
  mBodyMap
  scAPAatlas
  scQTLbase
</observation>
**Updated Plan:**
1. [✓] Check if the PDF files exist and verify their paths (Found at /root/biodatalab/benchmark/dataset/ADCdb/)
2. [ ] Read/extract text from ref2.pdf, ref4.pdf, and ref5.pdf
3. [ ] Analyze the content to extract ADC information (Name, mAb, Linker, Payload, Conjugate Type, DAR, Drug Status)
4. [ ] Create a structured dataset with the extracted information
5. [ ] Save the results to the specified CSV file path

Now let me extract text from all three PDF files:

<execute>
import pdfplumber
import os

# Correct paths
pdf_paths = {
    "ref2": "/root/biodatalab/benchmark/dataset/ADCdb/ref2.pdf",
    "ref4": "/root/biodatalab/benchmark/dataset/ADCdb/ref4.pdf",
    "ref5": "/root/biodatalab/benchmark/dataset/ADCdb/ref5.pdf"
}

# Extract text from each PDF
pdf_texts = {}

for ref, path in pdf_paths.items():
    print(f"\n{'='*60}")
    print(f"Extracting text from {ref}.pdf...")
    print(f"{'='*60}")
    
    text_content = []
    with pdfplumber.open(path) as pdf:
        print(f"Total pages: {len(pdf.pages)}")
        for i, page in enumerate(pdf.pages):
            text = page.extract_text()
            if text:
                text_content.append(f"--- Page {i+1} ---\n{text}")
    
    full_text = "\n\n".join(text_content)
    pdf_texts[ref] = full_text
    print(f"\nFirst 3000 characters of {ref}.pdf:")
    print(full_text[:3000])
    print(f"\n... (Total length: {len(full_text)} characters)")
</execute>
<observation>
============================================================
Extracting text from ref2.pdf...
============================================================
Total pages: 1

First 3000 characters of ref2.pdf:
--- Page 1 ---
HEMATOLOGIC MALIGNANCIES—LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
TPS7589 Poster Session
waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclo-
phosphamide,doxorubicin,andprednisoneplusrituximab(R-CHP)inpreviouslyuntreated
diffuse large B-cell lymphoma (DLBCL).
David Lavie, Muhit Ozcan, Ewa Paszkiewicz-Kozik, Eva Gonza´lez Barca, Tae Min Kim,
BenedettaPuccini,SiruoWang,RushdiaYusuf,PatriciaMarinello,WonSeogKim;HadassahMedical
Center,Jerusalem,Israel;AnkaraUniversitySchoolofMedicine,Ankara,Turkey;MariaSklodowska-
CurieNationalResearchInstituteofOncology,Warsaw,Poland;InstitutCatala` d’OncologiaHospitalet,
Barcelona University, IDIBELL, Barcelona, Spain; Seoul National University Hospital, Seoul, South
Korea; Unit AOU Careggi, Florence, Italy; Merck & Co., Inc., Rahway, NJ; Samsung Medical Center,
Seoul, South Korea
Background:Thepreferredfirst-lineregimenforDLBCLisrituximabwithcyclophosphamide,doxoru-
bicin,vincristine,andprednisone(R-CHOP);butnoveltherapiesareneeded.Arecentphase3study
showedthatreplacingvincristinewithanantibody-drugconjugate(ADC)isaviableapproach(TillyH
etal.NEnglJMed.2022;386:351-363).Receptortyrosinekinase–likeorphanreceptor1(ROR1)is
anoncofetalproteinthatisminimallyexpressedinadulttissuesandoverexpressedinDLBCL.ZVisan
ADCcomprisingahumanizedIgG1monoclonalanti-ROR1,aproteolyticallycleavablelinker,andthe
antimicrotubuleagent,monomethylauristatinE.Thesingle-arm,open-label,phase2waveLINE-007
study(NCT05406401)willinvestigateZVcombinedwithR-CHPinpatientswithpreviouslyuntreated
DLBCL.Part1isbeingconductedtodeterminesafetyandtolerabilityandrecommendedphase2dose
(RP2D)ofZVincombinationwithR-CHP.Part2willbeconductedtoinvestigateefficacyofZVatthe
RP2DwithR-CHP.Methods:Eligiblepatientswillbe$18yearsofageandhavepreviouslyuntreated
histologically confirmed DLBCL, positron emission tomography (PET)–positive disease verified by
blinded independent central review (BICR), an ECOG PS of 0 or 1, and adequate organ function.
Patients diagnosed with primary mediastinal B-cell lymphoma, with a history of transformation of
indolentdiseasetoDLBCL,oractivecentralnervoussystemlymphomawillbeexcluded.Approximately
60patientswillbeenrolled(part1,n=45;part2,n=15).Part1willuseamodifiedtoxicityprobability
intervaldesigntoestablishtheRP2DofZVwhenadministeredwithR-CHP.ThestartingdoseofZVwill
be1.75mg/kg(modifiedto1.5,2.0,2.25,or2.5mg/kg)administeredasanintravenousinfusionevery
3weeks(Q3W)incombinationwithR-CHP.Inpart2,anadditional15patientswillreceiveZVatRP2D
plusR-CHPQ3Wforupto6cyclesuntildiseaseprogressionperLugano2014criteria,unacceptable
toxicity, or withdrawal. Disease response assessment, computed tomography, and PET will occur at
baselineandcycles3and6.Adverseevents(AEs)willbemonitoredupto30daysaftercessationof
treatment(90daysforseriousAEs,or30daysifnewanticancertherapyisinitiated).AEswillbegraded
per National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Primary
end points a

... (Total length: 3821 characters)

============================================================
Extracting text from ref4.pdf...
============================================================
Total pages: 1

First 3000 characters of ref4.pdf:
--- Page 1 ---
DEVELOPMENTAL THERAPEUTICS—MOLECULARLYTARGETEDAGENTSAND TUMOR BIOLOGY
3001 Oral Abstract Session
BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in pa-
tientswithlocallyadvancedormetastaticsolidtumor:Resultsfromafirst-in-humanphase
1 study.
Li Zhang, Yuxiang Ma, Yuanyuan Zhao, Wenfeng Fang, Hongyun Zhao, Yan Huang, Yunpeng Yang,
Likun Chen, Xue Hou, Wen Zou, Muran Ding, Jing Yu, Suoyu Zhang, Junxian Wang, Sa Xiao,
Hongwei Wang, Hai Zhu, Martin Sebastian Olivo, Yi Zhu; Department of Medical Oncology, State
KeyLaboratoryofOncologyinSouthChina;CollaborativeInnovationCenterforCancerMedicine,Sun
Yat-sen University Cancer Center, Guangzhou, Guangdong, China; Department of Clinical Research,
SunYat-senUniversityCancerCenter,StateKeyLaboratoryofOncologyinSouthChina,Collaborative
Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma
Diagnosis and Therapy, Guangz, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen
UniversityCancerCenter&StateKeyLaboratoryofOncologyinSouthChina,CollaborativeInnovation
Center for Cancer Medicine, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen
UniversityCancerCenter&StateKeyLaboratoryofOncologyinSouthChina,CollaborativeInnovation
Center for Cancer Medicine, Guangzhou, Guangdong, China; Department of Clinical Research, Sun
Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative
InnovationCenterforCancerMedicine,Guangzhou,China;MedicalOncologyDepartment,SunYat-sen
University Cancer Center, Guangzhou, China; Dept. of Medical Oncology, Sun Yat-Sen University,
Guangzhou, China; Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China; Baili-Bio
(Chengdu)PharmaceuticalCo.,Ltd.,Chengdu,China;Bailipharm,ChengduSichuan,China;Sichuan
Baili-pharmaceuticalco.,LTD,Redmond,WA; SystImmune, Inc., Redmond,WA; SytImmune, INC.,
Redmond, WA
Background: BL-B01D1isafirst-in-classnovelADCconsistingofanEGFRxHER3bispecificantibody
linkedtoanovelTOP-Iinhibitorpayloadviaacleavablelinker.Wenowpresentsafety/efficacyresults
from a FIH phase I study of BL-B01D1. Methods: This study included patients (pts) with locally
advancedormetastaticsolidtumors.Fordoseescalation(D-ESC,i3+3),BL-B01D1wasadministered
intravenouslyatdosesof0.27,1.5,3.0mg/kgQW,2.5,3.0,3.5mg/kgD1D8Q3Wor4.5,5.0,6.0mg/
kgD1Q3W.Asubsetofptswereenrolledintodose-expansion(D-EXP)atQ3Wregimens.Results: Asof
Dec31,2022,150ptswereenrolledandreceivedatleastonedose(D-ESC,n=25;D-EXP,n=125).
DLTs were neutropenia, febrile neutropenia and thrombocytopenia at 3.0mg/kg QW and 3.5mg/kg
D1D8Q3W.TheMTDsweredeterminedtobe3.0mg/kgD1D8Q3Wand6.0mg/kgD1Q3W.D-EXPwas
carriedoutat2.5,3.0mg/kgD1D8Q3Wand4.5,5.0,6.0mg/kgD1Q3W.144ptswereenrolledacross
all Q3W dose levels (D-ESC and D-EXP), including 89 NSCLC, 7 SCLC, 27 nasopharyngeal cancer
(NPC),19HNSCCand2others.MostcommonTRAEs(.10%,allgrade/$G3)wereleukopenia(60%/
30%),neutropenia(51%/34%),anemia(45%/15%),thro

... (Total length: 4879 characters)

============================================================
Extracting text from ref5.pdf...
============================================================
Total pages: 1

First 3000 characters of ref5.pdf:
--- Page 1 ---
HEMATOLOGIC MALIGNANCIES—LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
TPS7595 Poster Session
waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as
monotherapy or in combination in patients (pts) with aggressive and indolent B-cell
malignancies.
PierLuigiZinzani,JiriMayer,OhadBenjamini,AlejandroBerkovits,IngridGlimelius,DonA.Stevens,
ArvindChaudhry,AhmetMuzafferDemir,Ramo´nGarciaSanz,WonSeogKim,FeiLi,JanuszHalka,
Ana Marin-Niebla, Muhit Ozcan, Ewa Paszkiewicz-Kozik, Armando Santoro, Yixin Ren, Uzor Ogbu,
PatriciaMarinello,WojciechJurczak;IRCCSAziendaOspedaliero-UniversitariadiBolognaIstitutodi
Ematologia“Sera`gnoli”,Bologna,Italy;FakultniNemocniceBrnoBohunice-InterniHematologickaa
Onkologicka Klinika, Brno, Czech Republic; Chaim Sheba Medical Center, Ramat Gan, Israel;
Inmunocel Chile, Santiago, Chile; Uppsala University and Akademiska sjukhuset-Blod-och tumor-
sjukdomar,Uppsala,Sweden;NortonWomen’sandChildren’sHospital–NortonCancerInstitute–St.
Matthews, Louisville, KY; Summit Cancer Centers, Spokane Valley, WA; Trakya University, Edirne,
Turkey; Hospital Universitario de Salamanca – Complejo Asistencial Universitario de Salamanca,
Salamanca, Spain; Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul,
South Korea; The First Affiliated Hospital of Nanchang University, Nanchang, China; Samodzielny
Publiczny Zaklad Opieki Zdrowotnej MSWiA w Olsztynie-Oddzial Kliniczny Hematologii, Olsztyn,
Poland;HospitalUniversitariValld’Hebron,Barcelona,Spain;AnkaraUniversitySchoolofMedicine,
Ankara, Turkey; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland;
HumanitasUniversity,PieveEmanuele,andIRCCSHumanitasResearchHospital–HumanitasCancer
Center Rozzano, Milan, Italy; Merck & Co., Inc., Rahway, NJ; MSC National Research Institute of
Oncology, Krakow, Poland
Background:ROR1isatransmembraneproteinexpressedinhematologicmalignancies.Zilovertamab
vedotin (ZV) is an antibody-drug conjugate comprising a humanized IgG1 monoclonal anti-ROR1, a
proteolyticallycleavablelinker,andtheantimicrotubuleagentmonomethylauristatinE.Nemtabrutinib
isareversibleinhibitorofBrutonstyrosinekinase(BTK).ThecombinationofZVandaBTKihasthe
potentialforimprovedresponsesinB-cellmalignancies.ThewaveLINE-006study(NCT05458297)is
designedtoinvestigatesafetyandefficacyofZVasmonotherapyorincombinationwithnemtabrutinib
in pts with B-cell malignancies. Methods: Eligible pts are $18 years old with biopsy-proven and/or
histologically confirmed mantle cell lymphoma (MCL), Richter s transformation (RT), chronic lym-
phocytic leukemia (CLL), or follicular lymphoma (FL), relapsed or refractory (R/R) disease, ECOG
performance status of 0 to 2, and adequate organ function (table). Approximately 275 pts will be
enrolledin6cohorts(A-F;seetable).IncohortsAandB,patientswillreceiveZV2.5mg/kgIVQ3W.In
cohortC,30patientswillbeenrolledinasafetyrun-inphaseofZVincombinationwithnemtabrutinib,
thenanadditional15patientswillreceiveth

... (Total length: 4910 characters)
</observation>
**Updated Plan:**
1. [✓] Check if the PDF files exist and verify their paths (Found at /root/biodatalab/benchmark/dataset/ADCdb/)
2. [✓] Read/extract text from ref2.pdf, ref4.pdf, and ref5.pdf
3. [ ] Analyze the content to extract ADC information (Name, mAb, Linker, Payload, Conjugate Type, DAR, Drug Status)
4. [ ] Create a structured dataset with the extracted information
5. [ ] Save the results to the specified CSV file path

Let me analyze the full text from all PDFs to extract complete information:

<execute>
import pdfplumber
import os

# Re-extract full text from each PDF
pdf_paths = {
    "ref2": "/root/biodatalab/benchmark/dataset/ADCdb/ref2.pdf",
    "ref4": "/root/biodatalab/benchmark/dataset/ADCdb/ref4.pdf",
    "ref5": "/root/biodatalab/benchmark/dataset/ADCdb/ref5.pdf"
}

# Get full texts
full_texts = {}
for ref, path in pdf_paths.items():
    with pdfplumber.open(path) as pdf:
        full_text = ""
        for page in pdf.pages:
            text = page.extract_text()
            if text:
                full_text += text + "\n"
        full_texts[ref] = full_text
        print(f"\n{'='*70}")
        print(f"FULL TEXT FROM {ref}.pdf:")
        print(f"{'='*70}")
        print(full_text[:5000])
        if len(full_text) > 5000:
            print(f"\n... (continued, total length: {len(full_text)} chars)")
        print(f"\n{'='*70}")
</execute>
<observation>The output is too long to be added to context. Here are the first 10K characters...

======================================================================
FULL TEXT FROM ref2.pdf:
======================================================================
HEMATOLOGIC MALIGNANCIES—LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
TPS7589 Poster Session
waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclo-
phosphamide,doxorubicin,andprednisoneplusrituximab(R-CHP)inpreviouslyuntreated
diffuse large B-cell lymphoma (DLBCL).
David Lavie, Muhit Ozcan, Ewa Paszkiewicz-Kozik, Eva Gonza´lez Barca, Tae Min Kim,
BenedettaPuccini,SiruoWang,RushdiaYusuf,PatriciaMarinello,WonSeogKim;HadassahMedical
Center,Jerusalem,Israel;AnkaraUniversitySchoolofMedicine,Ankara,Turkey;MariaSklodowska-
CurieNationalResearchInstituteofOncology,Warsaw,Poland;InstitutCatala` d’OncologiaHospitalet,
Barcelona University, IDIBELL, Barcelona, Spain; Seoul National University Hospital, Seoul, South
Korea; Unit AOU Careggi, Florence, Italy; Merck & Co., Inc., Rahway, NJ; Samsung Medical Center,
Seoul, South Korea
Background:Thepreferredfirst-lineregimenforDLBCLisrituximabwithcyclophosphamide,doxoru-
bicin,vincristine,andprednisone(R-CHOP);butnoveltherapiesareneeded.Arecentphase3study
showedthatreplacingvincristinewithanantibody-drugconjugate(ADC)isaviableapproach(TillyH
etal.NEnglJMed.2022;386:351-363).Receptortyrosinekinase–likeorphanreceptor1(ROR1)is
anoncofetalproteinthatisminimallyexpressedinadulttissuesandoverexpressedinDLBCL.ZVisan
ADCcomprisingahumanizedIgG1monoclonalanti-ROR1,aproteolyticallycleavablelinker,andthe
antimicrotubuleagent,monomethylauristatinE.Thesingle-arm,open-label,phase2waveLINE-007
study(NCT05406401)willinvestigateZVcombinedwithR-CHPinpatientswithpreviouslyuntreated
DLBCL.Part1isbeingconductedtodeterminesafetyandtolerabilityandrecommendedphase2dose
(RP2D)ofZVincombinationwithR-CHP.Part2willbeconductedtoinvestigateefficacyofZVatthe
RP2DwithR-CHP.Methods:Eligiblepatientswillbe$18yearsofageandhavepreviouslyuntreated
histologically confirmed DLBCL, positron emission tomography (PET)–positive disease verified by
blinded independent central review (BICR), an ECOG PS of 0 or 1, and adequate organ function.
Patients diagnosed with primary mediastinal B-cell lymphoma, with a history of transformation of
indolentdiseasetoDLBCL,oractivecentralnervoussystemlymphomawillbeexcluded.Approximately
60patientswillbeenrolled(part1,n=45;part2,n=15).Part1willuseamodifiedtoxicityprobability
intervaldesigntoestablishtheRP2DofZVwhenadministeredwithR-CHP.ThestartingdoseofZVwill
be1.75mg/kg(modifiedto1.5,2.0,2.25,or2.5mg/kg)administeredasanintravenousinfusionevery
3weeks(Q3W)incombinationwithR-CHP.Inpart2,anadditional15patientswillreceiveZVatRP2D
plusR-CHPQ3Wforupto6cyclesuntildiseaseprogressionperLugano2014criteria,unacceptable
toxicity, or withdrawal. Disease response assessment, computed tomography, and PET will occur at
baselineandcycles3and6.Adverseevents(AEs)willbemonitoredupto30daysaftercessationof
treatment(90daysforseriousAEs,or30daysifnewanticancertherapyisinitiated).AEswillbegraded
per National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Primary
end points are safety and tolerability and RP2D for ZV in combination with R-CHP, and complete
response rate per Lugano 2014 criteria as assessed by the investigator. Secondary end points are
objective response rate and duration of response per Lugano 2014 criteria by investigator review.
Exploratoryendpointsincludeprogression-freesurvivalperLugano2014criteriabyBICRandoverall
survival. Recruitment is currently underway. Clinical trial information: NCT05406401. Research
Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
©2023byAmericanSocietyofClinicalOncology.Visitmeetings.asco.organdsearchbyabstractfordisclosureinformation.
331.111.300.291
morf
6202
,13
yraunaJ
no
331.111.3.291
yb
gro.sbupocsa
morf
dedaolnwoD
.devreser
sthgir
llA
.ygolocnO
lacinilC
fo
yteicoS
naciremA
6202
©
thgirypoC


======================================================================

======================================================================
FULL TEXT FROM ref4.pdf:
======================================================================
DEVELOPMENTAL THERAPEUTICS—MOLECULARLYTARGETEDAGENTSAND TUMOR BIOLOGY
3001 Oral Abstract Session
BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in pa-
tientswithlocallyadvancedormetastaticsolidtumor:Resultsfromafirst-in-humanphase
1 study.
Li Zhang, Yuxiang Ma, Yuanyuan Zhao, Wenfeng Fang, Hongyun Zhao, Yan Huang, Yunpeng Yang,
Likun Chen, Xue Hou, Wen Zou, Muran Ding, Jing Yu, Suoyu Zhang, Junxian Wang, Sa Xiao,
Hongwei Wang, Hai Zhu, Martin Sebastian Olivo, Yi Zhu; Department of Medical Oncology, State
KeyLaboratoryofOncologyinSouthChina;CollaborativeInnovationCenterforCancerMedicine,Sun
Yat-sen University Cancer Center, Guangzhou, Guangdong, China; Department of Clinical Research,
SunYat-senUniversityCancerCenter,StateKeyLaboratoryofOncologyinSouthChina,Collaborative
Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma
Diagnosis and Therapy, Guangz, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen
UniversityCancerCenter&StateKeyLaboratoryofOncologyinSouthChina,CollaborativeInnovation
Center for Cancer Medicine, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen
UniversityCancerCenter&StateKeyLaboratoryofOncologyinSouthChina,CollaborativeInnovation
Center for Cancer Medicine, Guangzhou, Guangdong, China; Department of Clinical Research, Sun
Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative
InnovationCenterforCancerMedicine,Guangzhou,China;MedicalOncologyDepartment,SunYat-sen
University Cancer Center, Guangzhou, China; Dept. of Medical Oncology, Sun Yat-Sen University,
Guangzhou, China; Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China; Baili-Bio
(Chengdu)PharmaceuticalCo.,Ltd.,Chengdu,China;Bailipharm,ChengduSichuan,China;Sichuan
Baili-pharmaceuticalco.,LTD,Redmond,WA; SystImmune, Inc., Redmond,WA; SytImmune, INC.,
Redmond, WA
Background: BL-B01D1isafirst-in-classnovelADCconsistingofanEGFRxHER3bispecificantibody
linkedtoanovelTOP-Iinhibitorpayloadviaacleavablelinker.Wenowpresentsafety/efficacyresults
from a FIH phase I study of BL-B01D1. Methods: This study included patients (pts) with locally
advancedormetastaticsolidtumors.Fordoseescalation(D-ESC,i3+3),BL-B01D1wasadministered
intravenouslyatdosesof0.27,1.5,3.0mg/kgQW,2.5,3.0,3.5mg/kgD1D8Q3Wor4.5,5.0,6.0mg/
kgD1Q3W.Asubsetofptswereenrolledintodose-expansion(D-EXP)atQ3Wregimens.Results: Asof
Dec31,2022,150ptswereenrolledandreceivedatleastonedose(D-ESC,n=25;D-EXP,n=125).
DLTs were neutropenia, febrile neutropenia and thrombocytopenia at 3.0mg/kg QW and 3.5mg/kg
D1D8Q3W.TheMTDsweredeterminedtobe3.0mg/kgD1D8Q3Wand6.0mg/kgD1Q3W.D-EXPwas
carriedoutat2.5,3.0mg/kgD1D8Q3Wand4.5,5.0,6.0mg/kgD1Q3W.144ptswereenrolledacross
all Q3W dose levels (D-ESC and D-EXP), including 89 NSCLC, 7 SCLC, 27 nasopharyngeal cancer
(NPC),19HNSCCand2others.MostcommonTRAEs(.10%,allgrade/$G3)wereleukopenia(60%/
30%),neutropenia(51%/34%),anemia(45%/15%),thrombocytopenia(44%/19%),alopecia(30%/
0%), nausea (29%/,1%), vomiting (28%/0%), asthenia (21%/,1%), decreased appetite (22%/
,1%),asthenia(21%/,1%),hypophagia(16%/0%),diarrhoea(15%/2%), mouth ulceration (15%/
,1%), rash (13%/0%). No ILD was observed. 122 pts were evaluable for efficacy (at least 1 tumor
assessment). PK and other details will be updated in the meeting. Conclusions: BL-B01D1 demon-
stratedencouragingefficacyinheavilypretreatedmetastatic/locallyadvancedsolidtumors,especially
in pts with EGFRm NSCLC. The safety profile showed adequate safety and tolerability. Clinical trial
information: NCT05194982. Research Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
NSCLC(EGFR- NSCLC
mut) (EGFRwt) (SCLC) (NPC) HNSCC
(n=34)1 (n=42)2 (n=7) (n=24) (n=13)
Medianpriortreatmentline 4(1-7) 2(1-8) 2(1-2) 3(1-9) 3(1-7)
(range)
Bestoverallresponse,n3
cPR 15 7 1 3 /
PR4 6 10 0 8 1
SD(nwithshrinkage) 10(10) 23(16) 5(4) 13(12) 9(8)
PD 3 2 1 / 3
ORR5,% 61.8 40.5 14.3 45.8 7.7
(95%CI) (43.6-77.8) (25.6-56.7) (0.4-57.9) (25.6- (0.2-36.0)
67.2)
DCR,% 91.2 95.2 85.7% 100% 76.9%
(95%CI) (76.3-98.1) (83.8-99.4) (42.1- (85.8- (46.2-
99.6) 100) 95.0)
1AllhadpriorEGFRTKI,88%(30/34)hadprior3rdgenEGFRTKIand68%(23/34)hadpriorplatinum-
basedchemotherapy(PBC).2AllhadpriorPBC,88%(37/42)hadpriorPD-1/L1andPBC.3Only49pts
had1tumorassessment,including8EGFRmutNSCLC,19EGFRwtNSCLC,10NPC,8HNSCCand4
SCLC.4IncludingptswhosePRswerenotyetconfirmedbutstillundertreatment.5During12/2022~01/
2023,treatmentdelayof26pts(11NSCLC,3HNSCC,10NPC,2SCLC)duetoCOVID-19hada
significantnegativeeffectontheir1stand/or2ndtumorassessment(s).
©2023byAmericanSocietyofClinicalOncology.Visitmeetings.asco.organdsearchbyabstractfordisclosureinformation.
331.111.300.291
morf
6202
,13
yraunaJ
no
331.111.3.291
yb
gro.sbupocsa
morf
dedaolnwoD
.devreser
sthgir
llA
.ygolocnO
lacinilC
fo
yteicoS
naciremA
6202
©
thgirypoC


======================================================================

======================================================================
FULL TEXT FROM ref5.pdf:
======================================================================
HEMATOLOGIC MALIGNANCIES—LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
TPS7595 Poster Session
waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as
monotherapy or in combination in patients (pts) with aggressive and indolent B-cell
malignancies.
PierLuigiZinzani,JiriMayer,OhadBenjamini,AlejandroBerkovits,IngridGlimelius,DonA.Stevens,
ArvindChaudhry,AhmetMuzafferDemir,Ramo´nGarciaSanz,WonSeogKim,FeiLi,JanuszHalka,
Ana Marin-Niebla, Muhit Ozcan, Ewa Paszkiewicz-Kozik, Armando Santoro, Yixin Ren, Uzor Ogbu,
PatriciaMarinello,WojciechJurczak;IRCCSAziendaOspedaliero-UniversitariadiBolognaIstitutodi
Ematologia“Sera`gnoli”,Bologna,Italy;FakultniNemocn</observation>
<execute>
import pdfplumber
import pandas as pd
import os

# Get full text from ref5.pdf to complete the analysis
ref5_path = "/root/biodatalab/benchmark/dataset/ADCdb/ref5.pdf"
with pdfplumber.open(ref5_path) as pdf:
    ref5_text = ""
    for page in pdf.pages:
        text = page.extract_text()
        if text:
            ref5_text += text + "\n"

print("Ref5 full text last part:")
print(ref5_text[-2000:])
</execute>
<observation>Ref5 full text last part:
etyrun-inphaseofZVincombinationwithnemtabrutinib,
thenanadditional15patientswillreceivetheRP2Dofthecombination.PatientsincohortD(schedule
optimization)willberandomized1:1toreceiveZV2.5mg/kgIVQ3W(arm1)orZV2.0mg/kgIVQ2/3W
(arm 2). Patients in cohorts E and F (efficacy expansion) will receive the dose and schedule of ZV
determined during schedule optimization. Each recipient of ZV or nemtabrutinib will receive the
assignedinterventionuntildiseaseprogression,unacceptabletoxicity,orotherdiscontinuationcriteria
aremet.Tumorscanswillbeperformedatbaseline,thenQ12Wuptoweek108,thenQ24Wthereafter.
Adverseevents(AEs)willbemonitoredandwillbegradedperNCICTCAEversion5.Theprimaryend
points are the safety and tolerability of ZV alone (cohort D) and in combination with nemtabrutinib
(cohortC),andtheobjectiveresponserateofZValone(cohortsA,B,D,E,andF)andincombination
with nemtabrutinib (cohort C). The secondary end points are the duration of response of ZV alone
(cohorts A, B, D, E, and F) and in combination with nemtabrutinib (cohort C) and the safety and
tolerabilityofZValone(cohortsA,B,E,andF).Clinicaltrialinformation:NCT05458297. Research
Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Cohort InclusionCriteria n Treatment
A R/RMCLafter$2therapiesincludingaBTKiandeitherreceivedor40 ZV2.5mg/kgIVQ3W
wasineligibleforCAR-Tcelltherapy
B R/RRTafter$1priortherapy 50
C R/RMCLto$1priortherapyandnopriorexposuretononcovalent 45 ZV2.0to2.5mg/kgIVQ3W
BTKi +
Nemtabrutinib65mgPOQD
D R/RCLLorFLafter$2priortherapies 80 Randomized1:1toreceive:
ZV2.5mg/kgIVQ3W(arm1)
or
ZV2.0mg/kgIVQ2/3W(arm2)
E R/RFLafter$2priortherapies 30ZVondoseandscheduledetermined
F R/RCLLafter$2priortherapies 30 incohortD
©2023byAmericanSocietyofClinicalOncology.Visitmeetings.asco.organdsearchbyabstractfordisclosureinformation.
331.111.300.291
morf
6202
,13
yraunaJ
no
331.111.3.291
yb
gro.sbupocsa
morf
dedaolnwoD
.devreser
sthgir
llA
.ygolocnO
lacinilC
fo
yteicoS
naciremA
6202
©
thgirypoC

</observation>
Now I have all the necessary information. Let me extract the ADC data from each paper and create the CSV file:

<execute>
import pandas as pd
import os

# Create the output directory if it doesn't exist
output_dir = "/root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5"
tmp_dir = "/root/autodl-tmp/biomni_v20260208_tmp/kimi-k2.5/adcdb_extract"

os.makedirs(output_dir, exist_ok=True)
os.makedirs(tmp_dir, exist_ok=True)

# Extracted ADC information from the papers
adc_data = [
    {
        "Paper": "ref2",
        "ADC Name": "Zilovertamab vedotin (ZV)",
        "mAb": "Humanized IgG1 monoclonal anti-ROR1",
        "Linker": "Proteolytically cleavable linker",
        "Payload": "Monomethyl auristatin E",
        "Conjugate Type": "N/A",
        "DAR": "N/A",
        "Drug Status": "Phase 2"
    },
    {
        "Paper": "ref4",
        "ADC Name": "BL-B01D1",
        "mAb": "EGFRxHER3 bispecific antibody",
        "Linker": "Cleavable linker",
        "Payload": "Novel TOP-I inhibitor",
        "Conjugate Type": "N/A",
        "DAR": "N/A",
        "Drug Status": "Phase 1"
    },
    {
        "Paper": "ref5",
        "ADC Name": "Zilovertamab vedotin (ZV)",
        "mAb": "Humanized IgG1 monoclonal anti-ROR1",
        "Linker": "Proteolytically cleavable linker",
        "Payload": "Monomethyl auristatin E",
        "Conjugate Type": "N/A",
        "DAR": "N/A",
        "Drug Status": "Phase 2"
    }
]

# Create DataFrame
df = pd.DataFrame(adc_data)

# Display the data
print("Extracted ADC Information:")
print("="*80)
print(df.to_string(index=False))
print("="*80)

# Save to CSV
output_path = os.path.join(output_dir, "adcdb_extract_1.csv")
df.to_csv(output_path, index=False)
print(f"\nData saved to: {output_path}")

# Verify the saved file
print("\nVerifying saved CSV file:")
saved_df = pd.read_csv(output_path)
print(saved_df.to_string(index=False))
</execute>
<observation>Extracted ADC Information:
================================================================================
Paper                  ADC Name                                 mAb                           Linker                 Payload Conjugate Type DAR Drug Status
 ref2 Zilovertamab vedotin (ZV) Humanized IgG1 monoclonal anti-ROR1 Proteolytically cleavable linker Monomethyl auristatin E            N/A N/A     Phase 2
 ref4                  BL-B01D1       EGFRxHER3 bispecific antibody                 Cleavable linker   Novel TOP-I inhibitor            N/A N/A     Phase 1
 ref5 Zilovertamab vedotin (ZV) Humanized IgG1 monoclonal anti-ROR1 Proteolytically cleavable linker Monomethyl auristatin E            N/A N/A     Phase 2
================================================================================

Data saved to: /root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/adcdb_extract_1.csv

Verifying saved CSV file:
Paper                  ADC Name                                 mAb                           Linker                 Payload  Conjugate Type  DAR Drug Status
 ref2 Zilovertamab vedotin (ZV) Humanized IgG1 monoclonal anti-ROR1 Proteolytically cleavable linker Monomethyl auristatin E             NaN  NaN     Phase 2
 ref4                  BL-B01D1       EGFRxHER3 bispecific antibody                 Cleavable linker   Novel TOP-I inhibitor             NaN  NaN     Phase 1
 ref5 Zilovertamab vedotin (ZV) Humanized IgG1 monoclonal anti-ROR1 Proteolytically cleavable linker Monomethyl auristatin E             NaN  NaN     Phase 2
</observation>
<execute>
import pandas as pd
import os

# Re-read with explicit NA handling to see actual file content
output_path = "/root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/adcdb_extract_1.csv"

# Read raw file content
with open(output_path, 'r') as f:
    content = f.read()
    print("Raw CSV file content:")
    print("="*80)
    print(content)
    print("="*80)

# Re-save ensuring N/A is a string
adc_data = [
    {
        "Paper": "ref2",
        "ADC Name": "Zilovertamab vedotin (ZV)",
        "mAb": "Humanized IgG1 monoclonal anti-ROR1",
        "Linker": "Proteolytically cleavable linker",
        "Payload": "Monomethyl auristatin E",
        "Conjugate Type": "N/A",
        "DAR": "N/A",
        "Drug Status": "Phase 2"
    },
    {
        "Paper": "ref4",
        "ADC Name": "BL-B01D1",
        "mAb": "EGFRxHER3 bispecific antibody",
        "Linker": "Cleavable linker",
        "Payload": "Novel TOP-I inhibitor",
        "Conjugate Type": "N/A",
        "DAR": "N/A",
        "Drug Status": "Phase 1"
    },
    {
        "Paper": "ref5",
        "ADC Name": "Zilovertamab vedotin (ZV)",
        "mAb": "Humanized IgG1 monoclonal anti-ROR1",
        "Linker": "Proteolytically cleavable linker",
        "Payload": "Monomethyl auristatin E",
        "Conjugate Type": "N/A",
        "DAR": "N/A",
        "Drug Status": "Phase 2"
    }
]

df = pd.DataFrame(adc_data)
df.to_csv(output_path, index=False, na_rep="N/A")

# Verify again
print("\nFinal verification - reading raw file:")
with open(output_path, 'r') as f:
    print(f.read())
</execute>
<observation>Raw CSV file content:
================================================================================
Paper,ADC Name,mAb,Linker,Payload,Conjugate Type,DAR,Drug Status
ref2,Zilovertamab vedotin (ZV),Humanized IgG1 monoclonal anti-ROR1,Proteolytically cleavable linker,Monomethyl auristatin E,N/A,N/A,Phase 2
ref4,BL-B01D1,EGFRxHER3 bispecific antibody,Cleavable linker,Novel TOP-I inhibitor,N/A,N/A,Phase 1
ref5,Zilovertamab vedotin (ZV),Humanized IgG1 monoclonal anti-ROR1,Proteolytically cleavable linker,Monomethyl auristatin E,N/A,N/A,Phase 2

================================================================================

Final verification - reading raw file:
Paper,ADC Name,mAb,Linker,Payload,Conjugate Type,DAR,Drug Status
ref2,Zilovertamab vedotin (ZV),Humanized IgG1 monoclonal anti-ROR1,Proteolytically cleavable linker,Monomethyl auristatin E,N/A,N/A,Phase 2
ref4,BL-B01D1,EGFRxHER3 bispecific antibody,Cleavable linker,Novel TOP-I inhibitor,N/A,N/A,Phase 1
ref5,Zilovertamab vedotin (ZV),Humanized IgG1 monoclonal anti-ROR1,Proteolytically cleavable linker,Monomethyl auristatin E,N/A,N/A,Phase 2

</observation>
Each response must include thinking process followed by either <execute> or <solution> tag. But there are no tags in the current response. Please follow the instruction, fix and regenerate the response again.
**Updated Plan:**
1. [✓] Check if the PDF files exist and verify their paths (Found at /root/biodatalab/benchmark/dataset/ADCdb/)
2. [✓] Read/extract text from ref2.pdf, ref4.pdf, and ref5.pdf
3. [✓] Analyze the content to extract ADC information (Name, mAb, Linker, Payload, Conjugate Type, DAR, Drug Status)
4. [✓] Create a structured dataset with the extracted information
5. [✓] Save the results to the specified CSV file path

The task has been completed successfully. I've extracted ADC pharmacological information from all three PDF files and saved them to the specified CSV file. The CSV file contains the required columns (Paper, ADC Name, mAb, Linker, Payload, Conjugate Type, DAR, Drug Status) with data for 3 ADCs:

1. **Ref2**: Zilovertamab vedotin (ZV) - A Phase 2 ADC with humanized IgG1 anti-ROR1 mAb, proteolytically cleavable linker, and monomethyl auristatin E payload
2. **Ref4**: BL-B01D1 - A Phase 1 first-in-class EGFRxHER3 bispecific ADC with cleavable linker and novel TOP-I inhibitor payload
3. **Ref5**: Zilovertamab vedotin (ZV) - Same ADC as ref2, in Phase 2 study for B-cell malignancies

<solution>
Successfully extracted ADC pharmacological information from the three literature sources (ref2.pdf, ref4.pdf, ref5.pdf) and saved the results to `/root/autodl-tmp/biomni_v20260208_pred_results/kimi-k2.5/adcdb_extract_1.csv`.

The CSV file contains 3 ADC entries with the following extracted information:

1. **ref2 - Zilovertamab vedotin (ZV)**: Humanized IgG1 monoclonal anti-ROR1 antibody, proteolytically cleavable linker, monomethyl auristatin E payload, Phase 2 status
2. **ref4 - BL-B01D1**: EGFRxHER3 bispecific antibody, cleavable linker, novel TOP-I inhibitor payload, Phase 1 status  
3. **ref5 - Zilovertamab vedotin (ZV)**: Humanized IgG1 monoclonal anti-ROR1 antibody, proteolytically cleavable linker, monomethyl auristatin E payload, Phase 2 status

All fields follow the required format with "N/A" for missing values (Conjugate Type and DAR were not specified in the literature).
</solution>